VEGFA and cancer: The clinical value of AVT as an anticancer agent is predicated on its high affinity and specific interactions with VEGF, effecting the blockade of VEGF receptors 1 and 2 signaling activity, which ultimately slows down cancer cell proliferation, migration, invasiveness, cancer stem cell self-renewal, stemness maintenance, and immune suppression [39,53].